Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance
2015 IASLC World Conference on Lung Cancer
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Howard Jack West, MD
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).
James R. Jett, MD
James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).
Tony Mok, MD, and Fred R. Hirsch, MD, PhD
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).
Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).
Lorraine Cheryl Pelosof, MD, PhD
Lorraine Cheryl Pelosof, MD, PhD, of UT Southwestern Medical Center, discusses her study findings, which demonstrate an increasing proportion of never-smokers among patients with non–small cell lung cancer (Abstract ORAL 22.01).